Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability: 2023-2025

Historic Non-Current Deferred Tax Liability for Iovance Biotherapeutics (IOVA) over the last 2 years, with Sep 2025 value amounting to $31.7 million.

  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability was N/A to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year change of. This contributed to the annual value of $32.3 million for FY2024, which is 86.29% up from last year.
  • Iovance Biotherapeutics' Non-Current Deferred Tax Liability amounted to $31.7 million in Q3 2025, which was down 8.74% from $34.7 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability peaked at $34.7 million during Q2 2025, and registered a low of $17.3 million during Q4 2023.
  • For the 3-year period, Iovance Biotherapeutics' Non-Current Deferred Tax Liability averaged around $27.5 million, with its median value being $31.8 million (2025).
  • As far as peak fluctuations go, Iovance Biotherapeutics' Non-Current Deferred Tax Liability spiked by 86.29% in 2024, and later dropped by 4.02% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $17.3 million in 2023, then spiked by 86.29% to $32.3 million in 2024, then declined by 4.02% to $31.7 million in 2025.
  • Its Non-Current Deferred Tax Liability was $31.7 million in Q3 2025, compared to $34.7 million in Q2 2025 and $32.0 million in Q1 2025.